ID   RMA.Trh4 Db KO
AC   CVCL_C0DE
SY   RMA.Trh4.Db-/-
DR   CancerTools; 157677
DR   Wikidata; Q114312803
DR   Ximbio; 157677
RX   PubMed=29399388;
CC   Knockout cell: Method=CRISPR/Cas9; MGI; MGI:95896; H2-D1.
CC   Genetic integration: Method=Transfection/transduction; Gene=FPbase; R9NL8; eGFP (Note=Enhanced GFP).
CC   Genetic integration: Method=Transfection/transduction; Gene=MGI; MGI:1919199; Cers5.
CC   Transformant: ChEBI; CHEBI_23994; Ethyl methanesulfonate (Methylsulfonic acid ethyl ester; MSEE).
CC   Transformant: NCBI_TaxID; 11938; Rauscher murine leukemia virus (R-MuLV).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: T-cell; CL=CL_0000084.
CC   Breed/subspecies: C57BL/6.
DI   NCIt; C21604; Mouse leukemia
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_C0DC ! RMA.Trh4
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 10-04-25; Version: 7
//
RX   PubMed=29399388; DOI=10.1080/2162402X.2017.1382793; PMCID=PMC5790395;
RA   Doorduijn E.M., Sluijter M., Marijt K.A., Querido B.J.,
RA   van der Burg S.H., van Hall T.;
RT   "T cells specific for a TAP-independent self-peptide remain naive in
RT   tumor-bearing mice and are fully exploitable for therapy.";
RL   OncoImmunology 7:e1382793.1-e1382793.10(2018).
//